Folic acid supplementation prevents high body fat-induced bone loss through TGR5 signaling pathways

Osteoporosis caused by bone loss is one of the serious global public health problems. Folic acid is a B vitamin with multiple physiological functions such as lipid regulation and antioxidant capacity, and its potential to improve bone loss has attracted our attention. Through NHANES database analysis, we found that folic acid intake was significantly correlated with whole-body bone mineral density (BMD) in people aged 20-60 years, and the association may be mediated by the body fat rate. Male C57Bl/6 mice were fed either a normal diet or a high-fat diet, and folic acid was added to drinking water for supplementation. Our results indicated that mice with high body fat showed bone microstructure damage and bone loss, while folic acid supplementation improved bone quality. At the same time, we found that mice with high body fat exhibited abnormal blood lipids, dysregulation of intestinal flora, and metabolic disorders. Folic acid supplementation improved these phenomena. Through the network analysis of intestinal flora and metabolites, we found that LCA and TGR5 may play important roles. The results showed that folic acid promoted the expression of LCA and TGR5 in mice, increased the phosphorylation of AMPK, and decreased the phosphorylation of NF-κB and ERK, thereby reducing bone loss. In summary, folic acid intake is closely related to BMD, and folic acid supplementation can prevent high body fat-induced bone loss. Our study provides new ideas and an experimental basis for preventing bone loss and osteoporosis.

Patient-centred measurement of recovery from day-case surgery using wrist worn accelerometers: a pilot and feasibility study

This pilot and feasibility study evaluated wrist-worn accelerometers to measure recovery from day-case surgery in comparison with daily quality of recovery-15 scores. The protocol was designed with extensive patient and public involvement and engagement, and delivered by a research network of anaesthesia trainees. Forty-eight patients recruited through pre-operative assessment clinics wore wrist accelerometers for 7 days before (pre-operative) and immediately after elective surgery (early postoperative), and again at 3 months (late postoperative). Validated activity and quality of recovery questionnaires were administered. Raw accelerometry data were archived and analysed using open source software. The mean (SD) number of valid days of accelerometer wear per participant in the pre-operative, early and late postoperative periods were 5.4 (1.7), 6.6 (1.1) and 6.6 (1.0) days, respectively. On the day after surgery, Euclidian norm minus one (a summary measure of raw accelerations), step count, light physical activity and moderate/vigorous physical activity decreased to 57%, 47%, 59% and 35% of baseline values, respectively. Activity increased progressively on a daily basis but had not returned to baseline values by 7 days. Patient questionnaires suggested subjective recovery by postoperative day 3 to 4; however, accelerometry data showed that activity levels had not returned to baseline at this point. All activity measures had returned to baseline by 3 months. Wrist-worn accelerometery is acceptable to patients and feasible as a surrogate measure for monitoring postoperative recovery from day-case surgery. Our results suggest that patients may overestimate their rate of recovery from day-case surgery, which has important implications for future research.

Gm6377 suppressed SP 2/0 xenograft tumor by down-regulating Myc transcription

PURPOSE

Disturbed process of B-cell differentiation into plasmablasts (PBs)/plasma cells (PCs) is involved in multiple myeloma (MM). New strategies will be required to eliminate the MM cell clone for a long-term disease control. Because of its PB-like characteristics, the mus musculus myeloma SP 2/0 cell line was used in this study to search novel targets for PBs/PCs.

METHODS/PATIENTS

Affymetrix microarrays and RNA-sequencing assays were used to search a novel different molecule (Gm6377) between PBs/PCs and mature B cells. Cell counting kit-8 (CCK8), flow cytometry (FACS), xenograft mouse model, and the luciferase reporter system were used to assess the effect of Gm6377 on SP 2/0 cell proliferation, cell cycle, tumor growth, and Myc promoter activation, respectively.

RESULTS

We found that B cells expressed a high level of Gm6377 mRNA, whereas Gm6377 mRNA was decreased in PCs. In addition, SP 2/0 cells also expressed low levels of Gm6377 mRNA. Critically, Gm6377 overexpression suppressed SP 2/0 cell proliferation but not cell cycle. Furthermore, Gm6377 overexpression suppressed tumor progression in the SP 2/0 xenograft mouse model. Finally, we found that Gm6377 suppressed SP 2/0 cell proliferation by reducing the activation of the Myc promoter.

CONCLUSIONS

These results suggest that Gm6377 suppresses myeloma SP 2/0 cell growth by suppressing Myc. Thus, modulation of Gm6377 may be a potential therapeutic way to treat MM.

Sequential treatment by polidocanol and radiofrequency ablation of large benign partially cystic thyroid nodules with solid components: Efficacy and safety

PURPOSE

The purpose of this study was to retrospectively evaluate the efficacy and safety of a sequential treatment including percutaneous polidocanol sclerotherapy and radiofrequency ablation (RFA) in terms of volume reduction and complication rate in large, benign, partially cystic thyroid nodules with solid components.

MATERIALS AND METHOD

From April 2017 to April 2019, 46 patients with 47 large benign partially cystic thyroid nodules underwent sequential treatment. There were 14 men and 32 women with a mean age of 49.9±11.5 (SD) years (range: 18-75 years). The volume of initial nodules was 12.7±12.3 (SD) mL (range: 2.16-75.62mL). Volume reduction after percutaneous polidocanol sclerotherapy and further RFA was evaluated respectively. Patients had clinical and ultrasound evaluations at a follow-up time of 12.1±5.3 (SD) months (range: 1.5-23.9 months). Technical success and complications were accessed retrospectively.

RESULTS

After unsatisfying results with polidocanol sclerotherapy alone the 46 patients with 47 large benign partially cystic thyroid nodules had further RFA. Mean volume reduction of 47 nodules was 90.5±11.3 (SD) % (range: 43.9-99.3%) one month after RFA, 94.9±6.2 (SD) % (range: 66.9-99.5%) three months after RFA, and 95.8±5.5 (SD) % (range: 71.0-99.8%) six months after RFA. No recurrence or nodule enlargement after RFA was observed at the last follow-up. The complication rate of RFA was 12.5% (8/46 patients), with minor complications only.

CONCLUSIONS

The sequential treatment regimen, including percutaneous polidocanol sclerotherapy and RFA, is an appropriate and safe treatment strategy for large benign partially cystic thyroid nodules with solid components.

Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma

AIM

To evaluate the safety, efficacy, and long-term outcomes of ultrasound-guided radiofrequency ablation (RFA) for the treatment of primary papillary thyroid microcarcinoma (PTMC).

MATERIALS AND METHODS

A total of 37 patients with 38 PTMC nodules underwent RFA at a power of 20 W between September 2014 and December 2017. The clinical data of these patients were reviewed retrospectively and analysed. Imaging studies of the nodules were conducted, and the patients' thyroid function was assessed before RFA; 1, 3, 6, and 12 months after RFA; and every 6 months thereafter. The volumes and volume reduction rate (VRR) of the nodules were also calculated.

RESULTS

RFA with a low power of 20 W was used in the treatment of 37 patients with 38 PTMC nodules. All nodules achieved complete ablation, no complications occurred, and thyroid function was not affected. During follow-up, the volume of the nodules gradually decreased. Twelve months after ablation, the mean volumes of the nodules significantly decreased to 0.01±0.03 ml with a VRR of 99.34±3.49%. At a median follow-up of 6 (range: 1-18) months, 37 of the 38 nodules were completely absorbed, and no recurrence was observed in all 37 patients.

CONCLUSIONS

Low-power RFA showed good safety and promising efficacy outcomes for the treatment of PTMC. In addition to surgery and active surveillance, RFA may be an alternative treatment option for patients with PTMC.

Positive nonsentinel lymph nodes are associated with poor survival in breast cancer: results from a retrospective study

PURPOSE

The prognostic value of nonsentinel lymph-node (NSLN) status in breast cancer remains unclear. This study was designed to investigate the prognostic value of NSLN status in SLN-positive breast cancer.

METHODS

Retrospective 873 consecutive primary breast cancer patients from a single institution who were SLN-positive and underwent axillary lymph-node dissection (ALND) were included. Patients with incomplete clinical information or loss of follow-up were excluded. Survival analysis in patients with the same number of positive LNs and patients belonging to the same American Joint Committee on Cancer (AJCC) node (N) classification was performed to establish a proposal for incorporating the NSLN status into the breast cancer staging system.

RESULTS

The median follow-up was 41 months. Positive NSLN status was a significantly unfavorable factor for recurrence-free survival (RFS) (HR: 4.31, P < 0.001) and distant recurrence-free survival (DRFS) (HR: 3.62, P < 0.001). The survival of patients with one positive SLN and one positive NSLN (N = 97) was significantly worse than that of patients with two positive SLNs (N = 68; RFS, P = 0.011; DRFS, P = 0.027). Positive NSLN status was a significantly unfavorable factor affecting survival in patients with the AJCC N1 classification (N = 806; RFS, HR: 2.85, P = 0.002; DRFS, HR: 2.81, P = 0.004). No significant difference in survival was found between LN-negative (N = 361) and NSLN-negative AJCC N1 classification (N = 363) patients.

CONCLUSIONS

Positive NSLN status has an independent prognostic value in breast cancer patients with 1-3 positive LNs, and the NSLN status should be incorporated into the breast cancer staging system.

Pr3+-doped heavy metal germanium tellurite glasses for irradiative light source in minimally invasive photodynamic therapy surgery

Pr3+-doped medium-low phonon energy heavy metal germanium tellurite (NZPGT) glasses have been fabricated and the intense multi-peak red fluorescence emissions of Pr3+ are exhibited. Judd-Ofelt parameters Ω2 = 3.14 × 10(-20)cm(2), Ω4 = 10.67 × 10(-20)cm(2) and Ω6 = 3.95 × 10(-20)cm(2) indicate a high asymmetrical and covalent environment in the optical glasses. The spontaneous emission probabilities A(ij) corresponding to the 1D2→3H4, 3P0→3H6, and 3P0→3F2 transitions are derived to be 1859.6, 6270.1 and 17276.3s(-1), respectively, and the relevant stimulated emission cross-sections σ(em) are 5.20 × 10(-21), 14.14 × 10(-21) and 126.77 × 10(-21)cm(2), confirming that the effectiveness of the red luminescence in Pr3+-doped NZPGT glasses. Under the commercial blue LED excitation, the radiant flux and the quantum yield for the red fluorescence of Pr3+ are solved to be 219μW and 11.80%, respectively. 85.24% photons of the fluorescence in the visible region are demonstrated to be located in 600-720nm wavelength range, which matches the excitation band of the most photosensitizers (PS), holding great promise for photodynamic therapy (PDT) treatment and clinical trials.

C3G, a guanine nucleotide exchange factor bound to adapter molecule c-Crk, has two alternative splicing forms

Two types of C3G cDNA were isolated from mouse 3T3-L1 adipocyte cDNA library. A 114-bp sequence in the middle of C3G cDNA is deleted in the short type cDNA. By RT-PCR analysis, it was found that these two types of C3G mRNA existed in all the mouse tissues. Sequence comparison revealed 88% nucleotide sequence identity between mouse and human C3G cDNA. Comparison of mouse C3G cDNA with the human genome database suggested that this 114-bp sequence comprised an entire exon, and it is confirmed by PCR analysis using mouse genomic DNA and cDNA template. These results indicate that two C3G mRNAs and proteins result from alternative RNA splicing.

c-Crk, a substrate of the insulin-like growth factor-1 receptor tyrosine kinase, functions as an early signal mediator in the adipocyte differentiation process

Differentiation of 3T3-L1 preadipocytes into adipocytes is induced by a combination of inducers, including a glucocorticoid, an agent that elevates cellular cAMP, and a ligand of the insulin-like growth factor-1 receptor. Previous studies have implicated protein-tyrosine phosphatase (PTPase) HA2, a homologue of PTPase 1B, in the signaling cascade initiated by the differentiation inducers. Vanadate, a potent PTPase inhibitor, blocks adipocyte differentiation at an early stage in the program, but has no effect on the mitotic clonal expansion required for differentiation. Exposure of preadipocytes to vanadate along with the inducing agents led to the accumulation of pp35, a phosphotyrosyl protein that is a substrate for PTPase HA2. pp35 was purified to homogeneity and shown by amino acid sequence and mass analyses of tryptic peptides to be c-Crk, a known cytoplasmic target of the insulin-like growth factor-1 receptor tyrosine kinase. Transfection of 3T3-L1 preadipocytes with a c-Crk antisense RNA expression vector markedly reduced c-Crk levels and prevented differentiation into adipocytes. Studies with C3G, a protein that binds to the SH3 domain in c-Crk, showed that phosphorylation of c-Crk rendered the SH3 domain inaccessible to C3G. Taken together, these findings indicate that locking c-Crk in the phosphorylated state with vanadate prevents its participation in the signaling system that initiates adipocyte differentiation.

[Characterization of slowly-growing mycobacteria species by capillary gas chromatography]

A method for the characterization of mycobacteria species by capillary gas chromatography is described. After strains of mycobacteria being hydrolyzed, saponified in an acidic solution, various methyl esters resulted from mycobacteria were studied on an OV-101 column at optimum chromatographic conditions. The constituents of 9 slowly-growing mycobacteria species were analyzed and the results showed that there were obvious differences between different mycobacteria species, but same characteristics were observed between strains of the same species. The 9 species can be identified by the ratio of peak height of C18:1, C18:0 and TBSA. They are C18:1>TBSA>C18:0 for M. tuberculosis, C18:0>C18:1>TBSA for M. triviale, TBSA>C18:1>C18:0 for M. intracellulare, TBSA>C18:0>C18:1 for M. avium and C18:1>C18:0>TBSA for M. bovis, M. kansasii, M. gordonae, M. nonchromogenicum and M. terrae respectively. The 5 latter species can be distinguished by the presence of characteristic peaks of iC16:1 and C19:0. 75 strains of clinical isolated mycobacteria were analysed at the same chromatographic conditions. The results showed that they belonged to 9 different species. The accuracy of the proposed method was examined according to biological analysis.

[Comparative experiment of gas chromatography determination of Mycobacterium bacillus]

Using capillary column gas chromatography (GC) technique for detecting cellular fatty acid, the test of the GC chromatograms of 26 reference Mycobacteria strains (freeze-dried strains and transfer growed strains at the improved Lowenstein-Jensen culture for three or four weeks) was performed. On the basis of the test, a comparison was made between the GC method and the conventional method for determination of 54 strains of non-tuberculous mycobacteria which were separated from clinical specimens, and the conformational rate of the two methods was 94 percent. At the same time, the relationship between the drug resistance and the changes of GC chromatograms of M. tuberculosis and M. bovis which were separated from clinical samples was observed. The results demonstrated that the GC method would achieve better results if combined with the bacterial growing speed, the condition of producing colour and the condition of growing at PNB and TCH culture during determining the mycobacterium strains which were separated from clinical specimens.